Beijing, China

Ning Shen

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Beijing Hanmi Pharmaceutical Co., Ltd.. Active years: 2016.


% Patents Active = 100.0

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ning Shen: Innovator in Pharmaceutical Science

Introduction

Ning Shen is a prominent inventor based in Beijing, China. She has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative therapeutic agents. Her work focuses on enhancing the efficacy of treatments for metabolic disorders.

Latest Patents

Ning Shen holds a patent for "Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof." This invention provides a GIP analog derived from GIP (1-29, SEQ ID NO: 1), which exhibits both GLP-1 agonist activity and GIPR stimulation activity. The amino acid sequence of the GIP analog is represented by the formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. Additionally, the invention includes a pharmaceutical composition comprising the GIP analog and its various uses.

Career Highlights

Ning Shen is affiliated with Beijing Hanmi Pharmaceutical Co., Ltd., where she continues to advance her research and development efforts. Her innovative work has positioned her as a key figure in the pharmaceutical industry, contributing to the development of new therapeutic options.

Collaborations

Ning has collaborated with notable colleagues, including Sunghwan Moon and Hai Yang. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Ning Shen's contributions to pharmaceutical science, particularly through her patented innovations, highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in treatment options for metabolic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…